Eupraxia Pharmaceuticals Valuation Multiples

Eupraxia Pharmaceuticals Overview

About Eupraxia Pharmaceuticals

Eupraxia Pharmaceuticals Inc is a clinical-stage biotechnology company focused on the development of locally delivered, extended-release alternatives to existing pharmaceuticals. Its product EP-104 is used for the treatment of osteoarthritis and eosinophilic esophagitis symptoms. The company leverages its proprietary Diffusphere technology to optimize drug delivery for applications with unmet medical needs.

Founded

2011

HQ

Employees

33

Website

eupraxiapharma.com

Sectors

BiopharmaceuticalsBioTech

Financials (LTM)

Revenue: —

EBITDA: ($32M)

EV

$386M

Valuation Multiples

Multiples.vc

Start free trial

Eupraxia Pharmaceuticals Financials

Eupraxia Pharmaceuticals reported last 12-month revenue of — and negative EBITDA of ($32M).

In the same LTM period, Eupraxia Pharmaceuticals generated — in gross profit, ($32M) in EBITDA losses, and had net loss of ($39M).

Eupraxia Pharmaceuticals P&L

In the most recent fiscal year, Eupraxia Pharmaceuticals reported revenue of — and EBITDA of ($32M).

Eupraxia Pharmaceuticals expects next 12-month revenue of XXX and NTM EBITDA of XXX

Eupraxia Pharmaceuticals Stock Performance

Eupraxia Pharmaceuticals has current market cap of $436M, and enterprise value of $386M.

Eupraxia Pharmaceuticals' stock price is $7.09.

Eupraxia Pharmaceuticals Valuation Multiples

Eupraxia Pharmaceuticals trades at (12.1x) EV/EBITDA.

Eupraxia Pharmaceuticals Financial Valuation Multiples

As of April 19, 2026, Eupraxia Pharmaceuticals has market cap of $436M and EV of $386M.

Equity research analysts estimate Eupraxia Pharmaceuticals' 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX

Eupraxia Pharmaceuticals has a P/E ratio of (11.1x).

Eupraxia Pharmaceuticals Margins & Growth Rates

Eupraxia Pharmaceuticals' revenue in the last fiscal year grew by —.

Eupraxia Pharmaceuticals' revenue per employee in the last FY averaged $0.0M, while opex per employee averaged $1.2M for the same period.

Eupraxia Pharmaceuticals Public Comps

See public comps and valuation multiples for other Biopharmaceuticals comps.

Eupraxia Pharmaceuticals M&A Activity

Eupraxia Pharmaceuticals acquired XXX companies to date.

Last acquisition by Eupraxia Pharmaceuticals was on XXXXXXXX, XXXXX. Eupraxia Pharmaceuticals acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).

Eupraxia Pharmaceuticals Investment Activity

Eupraxia Pharmaceuticals invested in XXX companies to date.

Eupraxia Pharmaceuticals made its latest investment on XXXXXXXX, XXXXX. Eupraxia Pharmaceuticals invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).